Investing in antibiotics to alleviate future catastrophic outcomes: What is the value of having an effective antibiotic to mitigate pandemic influenza?
Identifieur interne : 001F24 ( Ncbi/Merge ); précédent : 001F23; suivant : 001F25Investing in antibiotics to alleviate future catastrophic outcomes: What is the value of having an effective antibiotic to mitigate pandemic influenza?
Auteurs : Itamar Megiddo [Royaume-Uni] ; Dusan Drabik [Pays-Bas] ; Tim Bedford [Royaume-Uni] ; Alec Morton [Royaume-Uni] ; Justus Wesseler [Pays-Bas] ; Ramanan Laxminarayan [Royaume-Uni]Source :
- Health economics [ 1099-1050 ] ; 2019.
Abstract
Over 95% of post-mortem samples from the 1918 pandemic, which caused 50 to 100 million deaths, showed bacterial infection complications. The introduction of antibiotics in the 1940s has since reduced the risk of bacterial infections, but growing resistance to antibiotics could increase the toll from future influenza pandemics if secondary bacterial infections are as serious as in 1918, or even if they are less severe. We develop a valuation model of the option to withhold wide use of an antibiotic until significant outbreaks such as pandemic influenza or foodborne diseases are identified. Using real options theory, we derive conditions under which withholding wide use is beneficial, and calculate the option value for influenza pandemic scenarios that lead to secondary infections with a resistant Staphylococcus aureus strain. We find that the value of withholding an effective novel oral antibiotic can be positive and significant unless the pandemic is mild and causes few secondary infections with the resistant strain or if most patients can be treated intravenously. Although the option value is sensitive to parameter uncertainty, our results suggest that further analysis on a case-by-case basis could guide investment in novel agents as well as strategies on how to use them.
DOI: 10.1002/hec.3867
PubMed: 30746802
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000170
- to stream PubMed, to step Curation: 000170
- to stream PubMed, to step Checkpoint: 000129
Links to Exploration step
pubmed:30746802Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Investing in antibiotics to alleviate future catastrophic outcomes: What is the value of having an effective antibiotic to mitigate pandemic influenza?</title>
<author><name sortKey="Megiddo, Itamar" sort="Megiddo, Itamar" uniqKey="Megiddo I" first="Itamar" last="Megiddo">Itamar Megiddo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Management Science, University of Strathclyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Drabik, Dusan" sort="Drabik, Dusan" uniqKey="Drabik D" first="Dusan" last="Drabik">Dusan Drabik</name>
<affiliation wicri:level="4"><nlm:affiliation>Agricultural Economics and Rural Policy Group, Wageningen University, Wageningen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Agricultural Economics and Rural Policy Group, Wageningen University, Wageningen</wicri:regionArea>
<orgName type="university">Université de Wageningue</orgName>
<placeName><settlement type="city">Wageningue</settlement>
<region nuts="2">Gueldre (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bedford, Tim" sort="Bedford, Tim" uniqKey="Bedford T" first="Tim" last="Bedford">Tim Bedford</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Management Science, University of Strathclyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morton, Alec" sort="Morton, Alec" uniqKey="Morton A" first="Alec" last="Morton">Alec Morton</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Management Science, University of Strathclyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wesseler, Justus" sort="Wesseler, Justus" uniqKey="Wesseler J" first="Justus" last="Wesseler">Justus Wesseler</name>
<affiliation wicri:level="4"><nlm:affiliation>Agricultural Economics and Rural Policy Group, Wageningen University, Wageningen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Agricultural Economics and Rural Policy Group, Wageningen University, Wageningen</wicri:regionArea>
<orgName type="university">Université de Wageningue</orgName>
<placeName><settlement type="city">Wageningue</settlement>
<region nuts="2">Gueldre (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Laxminarayan, Ramanan" sort="Laxminarayan, Ramanan" uniqKey="Laxminarayan R" first="Ramanan" last="Laxminarayan">Ramanan Laxminarayan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Management Science, University of Strathclyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30746802</idno>
<idno type="pmid">30746802</idno>
<idno type="doi">10.1002/hec.3867</idno>
<idno type="wicri:Area/PubMed/Corpus">000170</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000170</idno>
<idno type="wicri:Area/PubMed/Curation">000170</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000170</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000129</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000129</idno>
<idno type="wicri:Area/Ncbi/Merge">001F24</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Investing in antibiotics to alleviate future catastrophic outcomes: What is the value of having an effective antibiotic to mitigate pandemic influenza?</title>
<author><name sortKey="Megiddo, Itamar" sort="Megiddo, Itamar" uniqKey="Megiddo I" first="Itamar" last="Megiddo">Itamar Megiddo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Management Science, University of Strathclyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Drabik, Dusan" sort="Drabik, Dusan" uniqKey="Drabik D" first="Dusan" last="Drabik">Dusan Drabik</name>
<affiliation wicri:level="4"><nlm:affiliation>Agricultural Economics and Rural Policy Group, Wageningen University, Wageningen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Agricultural Economics and Rural Policy Group, Wageningen University, Wageningen</wicri:regionArea>
<orgName type="university">Université de Wageningue</orgName>
<placeName><settlement type="city">Wageningue</settlement>
<region nuts="2">Gueldre (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bedford, Tim" sort="Bedford, Tim" uniqKey="Bedford T" first="Tim" last="Bedford">Tim Bedford</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Management Science, University of Strathclyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Morton, Alec" sort="Morton, Alec" uniqKey="Morton A" first="Alec" last="Morton">Alec Morton</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Management Science, University of Strathclyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wesseler, Justus" sort="Wesseler, Justus" uniqKey="Wesseler J" first="Justus" last="Wesseler">Justus Wesseler</name>
<affiliation wicri:level="4"><nlm:affiliation>Agricultural Economics and Rural Policy Group, Wageningen University, Wageningen, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Agricultural Economics and Rural Policy Group, Wageningen University, Wageningen</wicri:regionArea>
<orgName type="university">Université de Wageningue</orgName>
<placeName><settlement type="city">Wageningue</settlement>
<region nuts="2">Gueldre (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Laxminarayan, Ramanan" sort="Laxminarayan, Ramanan" uniqKey="Laxminarayan R" first="Ramanan" last="Laxminarayan">Ramanan Laxminarayan</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Management Science, University of Strathclyde, Glasgow</wicri:regionArea>
<wicri:noRegion>Glasgow</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Health economics</title>
<idno type="eISSN">1099-1050</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Over 95% of post-mortem samples from the 1918 pandemic, which caused 50 to 100 million deaths, showed bacterial infection complications. The introduction of antibiotics in the 1940s has since reduced the risk of bacterial infections, but growing resistance to antibiotics could increase the toll from future influenza pandemics if secondary bacterial infections are as serious as in 1918, or even if they are less severe. We develop a valuation model of the option to withhold wide use of an antibiotic until significant outbreaks such as pandemic influenza or foodborne diseases are identified. Using real options theory, we derive conditions under which withholding wide use is beneficial, and calculate the option value for influenza pandemic scenarios that lead to secondary infections with a resistant Staphylococcus aureus strain. We find that the value of withholding an effective novel oral antibiotic can be positive and significant unless the pandemic is mild and causes few secondary infections with the resistant strain or if most patients can be treated intravenously. Although the option value is sensitive to parameter uncertainty, our results suggest that further analysis on a case-by-case basis could guide investment in novel agents as well as strategies on how to use them.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">30746802</PMID>
<DateRevised><Year>2020</Year>
<Month>02</Month>
<Day>26</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1050</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>28</Volume>
<Issue>4</Issue>
<PubDate><Year>2019</Year>
<Month>04</Month>
</PubDate>
</JournalIssue>
<Title>Health economics</Title>
<ISOAbbreviation>Health Econ</ISOAbbreviation>
</Journal>
<ArticleTitle>Investing in antibiotics to alleviate future catastrophic outcomes: What is the value of having an effective antibiotic to mitigate pandemic influenza?</ArticleTitle>
<Pagination><MedlinePgn>556-571</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/hec.3867</ELocationID>
<Abstract><AbstractText>Over 95% of post-mortem samples from the 1918 pandemic, which caused 50 to 100 million deaths, showed bacterial infection complications. The introduction of antibiotics in the 1940s has since reduced the risk of bacterial infections, but growing resistance to antibiotics could increase the toll from future influenza pandemics if secondary bacterial infections are as serious as in 1918, or even if they are less severe. We develop a valuation model of the option to withhold wide use of an antibiotic until significant outbreaks such as pandemic influenza or foodborne diseases are identified. Using real options theory, we derive conditions under which withholding wide use is beneficial, and calculate the option value for influenza pandemic scenarios that lead to secondary infections with a resistant Staphylococcus aureus strain. We find that the value of withholding an effective novel oral antibiotic can be positive and significant unless the pandemic is mild and causes few secondary infections with the resistant strain or if most patients can be treated intravenously. Although the option value is sensitive to parameter uncertainty, our results suggest that further analysis on a case-by-case basis could guide investment in novel agents as well as strategies on how to use them.</AbstractText>
<CopyrightInformation>© 2019 John Wiley & Sons, Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Megiddo</LastName>
<ForeName>Itamar</ForeName>
<Initials>I</Initials>
<Identifier Source="ORCID">0000-0001-8391-6660</Identifier>
<AffiliationInfo><Affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Center for Disease Dynamics, Economics & Policy, Washington, DC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Drabik</LastName>
<ForeName>Dusan</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Agricultural Economics and Rural Policy Group, Wageningen University, Wageningen, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bedford</LastName>
<ForeName>Tim</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morton</LastName>
<ForeName>Alec</ForeName>
<Initials>A</Initials>
<Identifier Source="ORCID">0000-0003-3803-8517</Identifier>
<AffiliationInfo><Affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wesseler</LastName>
<ForeName>Justus</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Agricultural Economics and Rural Policy Group, Wageningen University, Wageningen, The Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Laxminarayan</LastName>
<ForeName>Ramanan</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Management Science, University of Strathclyde, Glasgow, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Center for Disease Dynamics, Economics & Policy, Washington, DC.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Princeton Environmental Institute, Princeton University, Princeton, New Jersey.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>n°115618</GrantID>
<Agency>Innovative Medicines Initiative</Agency>
<Country>International</Country>
</Grant>
<Grant><GrantID>71672160</GrantID>
<Agency>National Natural Science Foundation of China</Agency>
<Country>International</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>02</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Health Econ</MedlineTA>
<NlmUniqueID>9306780</NlmUniqueID>
<ISSNLinking>1057-9230</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">antibiotics</Keyword>
<Keyword MajorTopicYN="Y">antibiotics resistance</Keyword>
<Keyword MajorTopicYN="Y">insurance value</Keyword>
<Keyword MajorTopicYN="Y">pandemic influenza</Keyword>
<Keyword MajorTopicYN="Y">real options analysis</Keyword>
<Keyword MajorTopicYN="Y">secondary bacterial infections</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>04</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2018</Year>
<Month>11</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>12</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>2</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>2</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>2</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30746802</ArticleId>
<ArticleId IdType="doi">10.1002/hec.3867</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Pays-Bas</li>
<li>Royaume-Uni</li>
</country>
<region><li>Gueldre (province)</li>
</region>
<settlement><li>Wageningue</li>
</settlement>
<orgName><li>Université de Wageningue</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Megiddo, Itamar" sort="Megiddo, Itamar" uniqKey="Megiddo I" first="Itamar" last="Megiddo">Itamar Megiddo</name>
</noRegion>
<name sortKey="Bedford, Tim" sort="Bedford, Tim" uniqKey="Bedford T" first="Tim" last="Bedford">Tim Bedford</name>
<name sortKey="Laxminarayan, Ramanan" sort="Laxminarayan, Ramanan" uniqKey="Laxminarayan R" first="Ramanan" last="Laxminarayan">Ramanan Laxminarayan</name>
<name sortKey="Morton, Alec" sort="Morton, Alec" uniqKey="Morton A" first="Alec" last="Morton">Alec Morton</name>
</country>
<country name="Pays-Bas"><region name="Gueldre (province)"><name sortKey="Drabik, Dusan" sort="Drabik, Dusan" uniqKey="Drabik D" first="Dusan" last="Drabik">Dusan Drabik</name>
</region>
<name sortKey="Wesseler, Justus" sort="Wesseler, Justus" uniqKey="Wesseler J" first="Justus" last="Wesseler">Justus Wesseler</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001F24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:30746802 |texte= Investing in antibiotics to alleviate future catastrophic outcomes: What is the value of having an effective antibiotic to mitigate pandemic influenza? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:30746802" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |